A Phase 2 Randomized, Open Label Crossover Study to Compare ORMD-0801 Given Once Daily at Bedtime to ORMD-0801 Given Three Times Daily (45-90 Minutes Before Meals) in Subjects With Type 1 Diabetes
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Oramed Pharmaceuticals
Most Recent Events
- 30 Dec 2021 Status changed from recruiting to completed.
- 02 Mar 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2020.
- 09 Jan 2020 According to an Oramed Pharmaceuticals, results from this study are expected in the first quarter of 2020.